Data Characteristics for This Category
Peptide drug clinical trial pre-screening data primarily comes from preclinical research reports, toxicology reports, pharmacokinetic (ADME) data, in vitro efficacy data, and published literature. This data typically exists as a mix of unstructured text (e.g., PDF reports, Word documents) and structured data (e.g., physicochemical properties, sequence information in Excel spreadsheets, CSV files). Data update frequency is relatively low, concentrating around different milestones in drug development. Document structures vary; reports may include standard sections like abstract, introduction, materials and methods, results, and discussion, but often contain complex elements such as figures, tables, sequence information, and chemical structures. Common fields and units include molecular weight (Da), purity (%), half-life (h), Cmax (ng/mL), Tmax (h), and IC50 (nM). Different source reports may use varying unit representations, requiring unit standardization. Sequence information usually appears in FASTA format, sometimes including modification details.
Constraints Imposed by These Characteristics on "Workflow Orchestration"
The mixed structure of peptide drug data challenges information extraction nodes within a workflow. Unstructured reports require advanced text parsing capabilities to accurately identify and extract key efficacy, toxicology, and pharmacokinetic parameters. The specificity of sequence information demands that the workflow can process biological sequence data, for example, for similarity comparisons or modification site identification. Due to infrequent data updates, the need for real-time knowledge base synchronization is relatively low, but version management and traceability of historical data become important. The diversity of fields and units means that data standardization steps, including unit conversion and data cleaning, must be introduced to ensure the accuracy of subsequent large model inference. Furthermore, the uniqueness of peptide drugs, characterized by their structural complexity and diverse mechanisms of action, requires retrieval and inference modules within the workflow to understand and correlate multi-dimensional information. Examples include combining sequence features with efficacy data for potential toxicity prediction, or matching mechanisms of action with clinical indications.
Configuration Guidelines
| Configuration Item | Suggested Value | Rationale |
|---|---|---|
Chunk size | 500–800 characters | Balances the integrity of paragraphs in peptide drug reports with the efficiency of the model's context window, preventing truncation of critical information. |
Recall count | 10–15 entries | Ensures coverage of sufficient relevant preclinical data and literature snippets, improving pre-screening accuracy. |
Similarity threshold | 0.75–0.85 | Guarantees the relevance of retrieval results while allowing for a degree of semantic generalization to capture potential associations. |
Rerank result count | 5 entries | Focuses on the most relevant, high-quality document snippets, reducing the processing burden on the large model and enhancing inference efficiency. |
ParsingTimeout | 300 seconds | Accounts for peptide drug reports potentially containing numerous figures, tables, and complex layouts, providing ample time for document parsing. |
Knowledge Base Specified Files | Filter by Research Phase | For pre-screening specific clinical phases (e.g., Phase I, Phase II), concentrates the search on relevant documents for that phase, reducing interference. |
Three Common Pitfalls
- Symptom: Batch execution nodes fail to complete all loops during API calls, but online debugging works normally. Reason: API calls may have default request timeouts or resource limits, causing long-running batch tasks to be interrupted. Online debugging environments typically have more lenient restrictions.
- Symptom: Knowledge base search nodes cannot accurately retrieve relevant documents for specific peptide sequences. Reason: The knowledge base was not effectively indexed for sequence information during construction, or the retrieval strategy relies too heavily on text matching, failing to consider sequence similarity or structural features.
- Symptom: After referencing variables in an AI conversation, large model parameters (e.g., temperature) cannot be set. Reason: In variable reference mode, large model parameters might be locked to default values or determined by upstream nodes. Check the specific configuration of the large model node in the workflow to ensure parameters are adjustable or passed through other means.
How to Confirm Correct Configuration
- Select a batch of known positive and negative control peptide drug cases. Pre-screen them through the workflow and check if the output risk assessment results align with actual conditions.
- Randomly select several clinical trial pre-screening results. Trace back the referenced knowledge base snippets and data sources to verify the accuracy and completeness of information extraction.
- Simulate running the workflow under varying data volumes and document complexities. Observe if processing time and resource consumption are within acceptable limits and check for error logs.
- For critical efficacy and toxicology parameters, cross-reference the values and units extracted by the workflow with the original documents. Confirm that unit conversions are correctly performed.
The values provided are common starting points. Measure their effectiveness against your own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.